Imagine a precision-guided missile that only hits the 'broken' cells causing a baby's blood sugar to drop. Instead of removing the whole organ, which causes lifelong diabetes, this method uses a special light-activated dye to destroy only the problematic cells. It's like using a laser to remove a weed without digging up the entire garden.
Current treatments for Congenital hyperinsulinism either fail to prevent brain injury or require total organ removal, which causes lifelong diabetes and maldigestion.
A targeted photodynamic therapy (tPDT) system using EX700DX to selectively destroy hyperfunctioning beta cells.
If you are a drug developer dealing with the lack of registered causal therapies for Congenital hyperinsulinism — this project developed EX700DX, a photosensitizer that selectively targets beta cells to normalize blood glucose levels.
If you are a device maker dealing with the need for specialized surgical tools — this project requires CE certified laser devices to activate the tPDT process for minimally invasive therapy.
If you are a diagnostic company dealing with the need to identify specific cell targets — this project utilizes exendin 4 to specifically bind to beta cells for targeted therapy.
Based on available project data, the specific cost per treatment or pricing model is not provided.
The project is currently working toward human proof-of-concept studies and validating clinical grade EX700DX, meaning it is not yet at industrial scale.
The project mentions that the cutting-edge technology is exclusively available to the consortium partners, but specific licensing terms are not listed.
The project period runs from 2024-01-01 to 2029-12-31, during which they intend to perform human proof-of-concept studies.
It is designed as a minimally invasive targeted photodynamic therapy (tPDT) to replace or avoid the need for total pancreatectomy.
The consortium is research-heavy with 7 universities and 1 research institute, but it maintains a strategic industrial presence with 2 companies (both SMEs), representing a 17% industry ratio. This structure suggests a transition from academic discovery to clinical validation, supported by partners across 6 countries including the US and UK.
Contact STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM in the Netherlands.
Contact us to explore licensing opportunities for EX700DX technology.
